Tags : Mirikizumab

ViewPoints Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Mirikizumab.  Shots: @52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the […]Read More

Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for

Shots: The P-ll SERENITY study involves the assessing of Mirikizumab (200mg, 600mg, 1000mg) vs PBO in patients in the ratio of 2:1:1:2 with moderately to severely active CD. The P-II study includes 12wks. induction period and 40wks. continued treatment period, evaluating the safety and efficacy of multiple dosing regimens and two methods of administration @52wks. […]Read More

Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study

Shots: The P-III OASIS-2 study involves assessing mirikizumab vs PBO & Cosentyx (secukinumab) in 1,465 patients with mod. to sev. PsO. The patients were randomized in a (4:4:4:1) ratio to one of the following induction and maintenance period treatments: mirikizumab (250mg) @ 0, 4, 8, 12wks. followed by 250 & 125mg, q8w starting @16wks; 300mg […]Read More